目的 探讨厄贝沙坦联合贝那普利治疗慢性肾脏病的临床效果。方法 选取2019年8月—2020年7月和平县人民医院收治的76例慢性肾脏病患者，随机分为对照组和治疗组，每组各38例。对照组口服盐酸贝那普利片10～20 mg/次，1次/d。治疗组在对照组治疗基础上口服厄贝沙坦片75～150 mg/次，1次/d。两组患者连续治疗6个月。观察两组的临床疗效，比较两组血压、血肌酐、尿素氮、血浆白蛋白、24小时尿蛋白定量的变化情况。结果 治疗后，治疗组总有效率94.74%，显著高于对照组的78.95%（P<0.05）。治疗后，两组收缩压、舒张压、血肌酐、血尿素氮均较治疗前显著降低，但血浆白蛋白水平显著升高（P<0.05）；治疗后，治疗组血压和肾功能指标改善优于对照组（P<0.05）。两组治疗1、3、6个月24 h尿蛋白定量均较同组治疗前显著降低（P<0.05）；且治疗组24 h尿蛋白定量显著低于对照组治疗同期（P<0.05）。结论 厄贝沙坦联合贝那普利治疗慢性肾脏病具有较好的临床疗效，有利于减少蛋白尿，保护肾功能，延缓肾功能恶化，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of irbesartan combined with benazepril in treatment of chronic kidney disease. Methods A total of 76 patients with chronic kidney disease admitted to Heping County People's Hospital from August 2019 to July 2020 were randomly divided into control group and treatment group, with 38 patients in each group. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 — 20 mg/time, once daily. Patients in the treatment group were po administered with Irbesartan Tablets on the basis of the control group, 75—150 mg/time, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, the changes of blood pressure, serum creatinine, urea nitrogen, plasma albumin and 24 h urinary protein were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 94.74%, which was significantly higher than that of the control group (78.95%, P<0.05). After treatment, systolic blood pressure, diastolic blood pressure, serum creatinine, and blood urea nitrogen in both groups were significantly decreased, but plasma albumin level was significantly increased (P<0.05). After treatment, the improvement of blood pressure and renal function in the treatment group was better than that in the control group (P<0.05). 24 h Urinary protein level in two groups at 1, 3, and 6 months was significantly lower than that before treatment (P<0.05). The 24 h urinary protein level in the treatment group was significantly lower than that in the control group at the same time of the treatment (P<0.05). Conclusion Irbesartan combined with benazepril has a good clinical effect in treatment of chronic kidney disease, and can reduce proteinuria, protect renal function,delay the deterioration of renal function, which has a certain clinical application value.

R983

河源市科技计划项目（河科2019032）